EXPE:NASDAQExpedia Group, Inc. Analysis
Data as of 2026-04-01 - not real-time
$227.67
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Expedia Group is trading at roughly $227, well below its discounted cash‑flow fair value of $518, implying a substantial valuation gap. The company delivers impressive profitability, with a gross margin near 90% and an operating margin of 15%, while revenue is growing at double‑digit rates (≈11%). Return on equity is exceptionally high at 48%, and cash flow generation remains robust, supporting a modest dividend payout of 0.73% and a low payout ratio. However, the balance sheet is leveraged, reflected in a debt‑to‑equity ratio exceeding 250% and a beta of 1.5, which amplifies market‑related risk. Technical indicators are mixed: the 20‑day and 50‑day SMAs sit above the current price, the MACD histogram is negative, and volume trends are decreasing, suggesting short‑term pressure. The RSI at 46 points to a neutral stance, and the stock is poised near a support level of $220. Recent news adds nuance—an AI‑beneficiary upgrade from Jefferies and a dividend hike sparked a 13% rally, while Citigroup trimmed its price target to $225, maintaining a neutral rating.
Overall, the fundamentals and valuation metrics favor a longer‑term upside, but the near‑term technical weakness and high leverage warrant caution. Investors should weigh the upside potential from the DCF gap and strong earnings growth against the volatility inherent in a cyclical travel sector and the company’s debt load.
Overall, the fundamentals and valuation metrics favor a longer‑term upside, but the near‑term technical weakness and high leverage warrant caution. Investors should weigh the upside potential from the DCF gap and strong earnings growth against the volatility inherent in a cyclical travel sector and the company’s debt load.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- MACD bearish and price below short‑term moving averages
- Decreasing volume indicating waning buying pressure
- Proximity to support level around $220
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation upside versus DCF fair value
- Strong earnings growth and high ROE
- Positive catalyst from AI upgrade and dividend increase
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Sustained high margins and cash flow generation
- Long‑term travel demand supporting revenue expansion
- Undervaluation relative to intrinsic value offering multi‑year upside
Key Metrics & Analysis
Financial Health
Revenue Growth11.40%
Profit Margin8.78%
P/E Ratio23.2
ROE48.67%
ROA5.77%
Debt/Equity254.69
P/B Ratio21.7
Op. Cash Flow$3.9B
Free Cash Flow$2.9B
Technical Analysis
TrendBullish
RSI46.1
Support$220.67
Resistance$252.23
MA 20$235.08
MA 50$234.25
MA 200$227.69
MACDBearish
VolumeDecreasing
Fear & Greed Index77.61
Valuation
Fair Value$517.60
Target Price$283.12
Upside/Downside24.35%
GradeUndervalued
TypeBlend
Dividend Yield0.73%
Risk Assessment
Beta1.50
Volatility57.60%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.